Date: February 8, 2012

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Revisions to the Communicable Disease Control Manual – Chapter II, Immunization Program

Please note the following changes to the Communicable Disease Control Manual, Chapter II - Immunization Program:

(1) SECTION IIA, IMMUNIZATION SCHEDULES

Page 3, “1.1.2 Schedule B: Children ≥1 Year but Less Than 7 years of age when Starting Immunization:”
- Bullets on page repositioned for accuracy. Content unchanged.

Page 4, “1.2.1 Alternate Schedule B: Schedule B: Children ≥1 Year but Less Than 7 years of age when Starting Immunization:”
- Footnote  added, to replace a duplicate footnote . Content unchanged.

Page 5, “1.3 Hib Schedule When the Basic Schedule Has Been Delayed:”
- Footnote  added, to replace a duplicate footnote . Content unchanged.

Page 12, “3.1 Minimum Intervals between Vaccine Doses Table:”
- Hepatitis A vaccine minimum age for first dose (6 months) and minimum interval between dose 1 and dose 2 (6 months) added.
- Footnote  expanded to indicate minimum intervals for Meningococcal Conjugate C vaccine in a high risk schedule.

Administrative Circular 2012:03
(2) SECTION VII, BIOLOGICAL PRODUCTS:

Pages 62c and 62d, “Rotavirus vaccine (Human rotavirus, live attenuated, oral vaccine) (Rotarix™):”
- Under “Initial Series” clarification that dose 1 of the vaccine is given to infants presenting “at the 2 month immunization visit” and dose 2 is given “at the 4 month immunization visit.”
- Under “Contraindications” added “Uncorrected congenital gastrointestinal conditions (e.g., Meckel’s diverticulum)”
- Under “Precautions” clarified the upper limit for scheduling of the first dose to “20 weeks less 1 day”.
- Under “Adverse Events,” revised the list to include the common events (diarrhea and irritability) and the uncommon events (abdominal pain, flatulence and dermatitis).
- Footnote 6 clarified to read “8 months less 1 day of age”.

Page 78, “Varicella Vaccine (live attenuated viral) Varivax® III and Varilrix®:”
- Replaced a missing footnote 6 symbol for candidates for solid organ transplant.

Page 81, “Varicella Zoster Vaccine (live attenuated viral) (ZOSTAVAX™):”
- Under “Precautions,” removed number 6 “Delay ZOSTAVAX™ administration for 3 months after a dose of intravenous immunoglobulin (IVIG)”. As noted under “Special Considerations” ZOSTAVAX™ can be given at any time before, at the same time, or after administration of any blood product including antibody-containing products.

Please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program”

Section IIA: Immunization Schedules
Pages 3, 4, 5 & 12 Dated January 2012

Section VII: Biological Products
Pages 62c, 62d, 78 & 81 Dated January 2012
Please insert the following pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program

Section IIA
Pages 3, 4, 5 & 12  Dated February 2012

Section VII: Biological Products
Pages 62c, 62d, 78 & 81  Dated February 2012

If you have any questions or concerns, please contact Cheryl McIntyre, Clinical Nurse Specialist, or Brittany Deeter, Public Health Resource Nurse, at telephone (604) 707-2519, fax (604) 707-2516 or by email at cheryl.mcintyre@bccdc.ca or brittany.deeter@bccdc.ca

Sincerely,

Dr. Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:

Dr. Perry Kendall  Dr. Eric Young
Provincial Health Officer  Deputy Provincial Health Officer

Dr. Bob Fisk  Craig Thompson
Medical Consultant  Director, Immunization- CD Prevention
Non-Communicable Disease

Warren O’Briain
Executive Director
Communicable Disease Prevention, Harm Reduction and Mental Health Promotion